YJYunan Ji

Yunan Ji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yunan Ji has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends in Venture Capital Investment in AI-Driven Biopharmaceutical Startups

    by Abhishek Bazaz, Yunan Ji, Mariana P Socal, So-Yeon Kang

    This study analyzes 2010-2024 venture capital trends in international artificial intelligence–driven biopharmaceutical startups, revealing rapid growth in discovery tool investments and concentrated US funding in California and Massachusetts.


  • Trends In Biopharmaceutical Clinical Trials After Medicare Drug Price Negotiation

    by So-Yeon Kang, Mingqian Liu, Yunan Ji

    The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs, with implications for innovation. Using ClinicalTrials.gov data on biopharmaceutical trials initiated during 2015-24, we found that overall trial activity remained stable, returning to prepandemic levels, but manufacturers with drugs subject to negotiation initiated fewer trials, particularly in certain cancers.


  • Open Access

    Trends in Venture Capital Investment in AI-Driven Biopharmaceutical Startups (Preprint)

    by Abhishek Bazaz, Yunan Ji, Mariana P Socal, So-Yeon Kang

    UNSTRUCTURED This study analyzes 2010-2024 venture capital trends in international artificial intelligence–driven biopharmaceutical startups, revealing rapid growth in discovery tool investments and concentrated US funding in California and Massachusetts.

  • Open Access

    Provision of Hospital Price Information After Increases in Financial Penalties for Failure to Comply With a US Federal Hospital Price Transparency Rule

    by Edward Kong, Yunan Ji

    Importance: Price transparency regulations aim to help patients make informed decisions about medical care, but enforcing these rules is a policy challenge. There may be an association between financial penalties and hospital compliance for enforcing price transparency regulations.Objective: To evaluate the association between financial penalties and acute care hospital compliance with the 2021 Centers for Medicare & Medicaid Services (CMS) Price Transparency Rule.Design, Setting, and Participants: This cohort study uses an instrumental variable design to evaluate the responses of 4377 acute care hospitals in the US operating in 2021 and 2022 to changes in financial penalties in the context of a federal rule requiring hospitals to disclose privately negotiated prices.Exposure: Changes in noncompliance penalties between 2021 and 2022 based on a nonlinear function of bed counts.Main Outcomes and Measures: Whether hospitals publicly posted a machine-readable file with private, payer-specific negotiated prices at the service-code level. Negative controls were used to address confounding.Results: The final sample included 4377 hospitals. Compliance increased from 70.4% (n = 3082) in 2021 to 87.7% (n = 3841) in 2022, with 90.2% of hospitals (n = 3948) reporting prices in at least 1 year. Noncompliance penalties increased from $109 500/y in 2021 to a mean (SD) of $510 976 ($534 149)/y in 2022. Penalties in 2022 were substantial, averaging 0.49% of total hospital revenue, 0.53% of total hospital costs, and 1.3% of total employee wages. Compliance increases were significantly positively correlated with penalty increases: a $500 000 increase in penalty was associated with a 2.9–percentage point (95% CI, 1.7-4.2 percentage points; P < .001) increase in compliance. Results were robust to controlling for observable hospital characteristics. No associations were found for preperiod (2021) compliance or ranges of bed counts where penalties do not vary.Conclusions and Relevance: In this cohort study of 4377 hospitals, compliance with the CMS Price Transparency Rule was associated with increased financial penalties. These findings are relevant for the enforcement of other regulations designed to promote transparency in health care.


  • Open Access

    Financial Incentives to Facilities and Clinicians Treating Patients With End-stage Kidney Disease and Use of Home Dialysis

    by Yunan Ji, Liran Einav, Neale Mahoney, Amy Finkelstein

    Importance: Home dialysis rates for end-stage kidney disease (ESKD) treatment are substantially lower in the US than in other high-income countries, yet there is limited knowledge on how to increase these rates.Objective: To report results from the first year of a nationwide randomized clinical trial that provides financial incentives to ESKD facilities and managing clinicians to increase home dialysis rates.Design, Setting, and Participants: Results were analyzed from the first year of the End-Stage Renal Disease Treatment Choice (ETC) model, a multiyear, mandatory-participation randomized clinical trial designed and implemented by the US Center for Medicare & Medicaid Innovation. Data were reported on Medicare patients with ESKD 66 years or older who initiated treatment with dialysis in 2021, with data collection through December 31, 2021; the study included all eligible ESKD facilities and managing clinicians. Eligible hospital referral regions (HRRs) were randomly assigned to the ETC (91 HRRs) or a control group (211 HRRs).Interventions: The ESKD facilities and managing clinicians received financial incentives for home dialysis use.Main Outcomes and Measures: The primary outcome was the percentage of patients with ESKD who received any home dialysis during the first 90 days of treatment. Secondary outcomes included other measures of home dialysis and patient volume and characteristics.Results: Among the 302 HRRs eligible for randomization, 18 621 eligible patients initiated dialysis treatment during the study period (mean [SD] age, 74.8 [1.05] years; 7856 women [42.1%]; 10 765 men [57.9%]; 859 Asian [5.2%], 3280 [17.7%] Black, 730 [4.3%] Hispanic, 239 North American Native, and 12 394 managing clinicians. The mean (SD) share of patients with any home dialysis during the first 90 days was 20.6% (7.8%) in the control group and was 0.12 percentage points higher (95% CI, −1.42 to 1.65 percentage points; P = .88) in the ETC group, a statistically nonsignificant difference. None of the secondary outcomes differed significantly between groups.Conclusions and Relevance: The trial results found that in the first year of the US Center for Medicare & Medicaid Innovation–designed ETC model, HRRs assigned to the model did not have statistically significantly different rates in home dialysis compared with control HRRs. This raises questions about the efficacy of the financial incentives provided, although further evaluation is needed, as the size of these incentives will increase in subsequent years.Trial Registration: ClinicalTrials.gov Identifier: NCT05005572